kabutan

Perseus Proteomics continues to rise on subsidy for aggressive NK-cell leukemia treatment drug development

Thu Apr 2, 2026 11:03 am JST Catalyst

Perseus Proteomics Inc. <4882> continued to rise. After the close of trading on the 1st, the company announced that it has been approved to receive \100 million in fiscal 2026 medical research and development promotion project subsidies from the Japan Agency for Medical Research and Development (AMED) for the development of "PPMX-T003," a treatment drug for aggressive NK-cell leukemia, which has been viewed as positive news.

The support program is scheduled to provide assistance for up to three fiscal years starting from fiscal 2025, covering expenses related to the implementation of investigator-initiated clinical trials of "PPMX-T003" for aggressive NK-cell leukemia, with the subsidy amount determined each fiscal year. The current subsidy is scheduled to be received in the fiscal year ending March 2027. The company stated that the impact on its earnings for the fiscal year ending March 2027 will be minimal.

Source: MINKABU PRESS

Related Articles